Benralizumab Matches Mepolizumab for Rare Vasculitis

(MedPage Today) -- WASHINGTON -- Treatment with benralizumab (Fasenra) was noninferior to mepolizumab (Nucala) for relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), the randomized MANDARA trial showed. Among 140 patients...
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news